Patents Examined by Fozia Hamud
  • Syndecan-2 compositions and methods of use
    Patent number: 10251934
    Abstract: SDC2, compositions that comprise SDC2, vectors encoding SDC2 and compounds that modulate expression of SDC2 by cells are used for treatment of mammalian, e.g. human, cells to achieve immunomodulation or for other specific therapeutic interventions. Cells are treated by combining the cells with SDC2, treating the cells with an antibody or fragment thereof that binds SDC2 or modulating expression or activity of SDC2 by the cells. Cells or tissue are derived from treated cells for therapeutic uses based on their immunomodulatory or other therapeutic properties.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: April 9, 2019
    Assignee: Orbsen Therapeutics Limited
    Inventor: Stephen Joseph Elliman
  • IL22 immunoconjugates
    Patent number: 10246502
    Abstract: The application relates to a conjugate comprising interleukin-22 (IL22) and an antibody molecule. The antibody molecule preferably binds an antigen associated with angiogenesis, such as the ED-A isoform of fibronectin. In particular, the application relates to the therapeutic use of such conjugates in the treatment of a disease/disorder, such as autoimmune diseases, including inflammatory bowel disease (IBD).
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: April 2, 2019
    Assignee: Philogen S.P.A.
    Inventors: Franziska Sophie Bootz, Dario Neri
  • Anti-ED-A immunoconjugates for inflammatory bowel disease
    Patent number: 10239939
    Abstract: Specific binding members that bind the ED-A isoform of fibronectin for use in methods of treatment, diagnosis, detection and/or imaging of inflammatory bowel disease (IBD), and/or for use in delivery to the IBD tissue of a molecule conjugated to the specific binding member. The specific binding member may, for example, be conjugated to an immunosupressive or anti-inflammatory molecule, such as interleukin-10.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: March 26, 2019
    Assignee: PHILOGEN S.P.A.
    Inventors: Giovanni Neri, Kathrin Schwager, Melanie C. Ruzek, Denise M. O'hara, Jianqing Chen
  • Isolated host cells expressing anti-IL-6 antibodies
    Patent number: 10233239
    Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making the anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: March 19, 2019
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T. L. Smith
  • Tear lipocalin muteins binding IL-4 R alpha
    Patent number: 10232014
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: March 19, 2019
    Assignees: PIERIS PHARMACEUTICALS GMBH, ASTRAZENECA AB
    Inventors: Andreas Hohlbaum, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfeld, Hans-Juergen Christian
  • Antagonists of IL-6 to raise albumin and/or lower CRP
    Patent number: 10227404
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: March 12, 2019
    Assignee: ALDERBIO HOLDINGS LLC
    Inventor: Jeffrey T. L. Smith
  • IL-15 heterodimeric protein and uses thereof
    Patent number: 10206980
    Abstract: Provided is an IL-15 heterodimeric protein, such as an IL-15/IL-15R? heterodimeric protein. The IL-15 heterodimeric protein contains protein (I) and protein (II). Protein (I) is recombinantly produced by combining IL-15 or a variant thereof with a first Fc variant, and protein (II) is a second Fc variant, or recombinantly produced by combining IL-15R? or a variant thereof with a second Fc variant. The first Fc variant and the second Fc variant are preferably linked via a “Knob-into-Hole” mode. Also provided are methods of using the IL-15 heterodimeric proteins to modulate an immune response. The provided IL-15 heterodimeric proteins have significant anti-tumor activity, better biological activity and prolonged in vivo half-life compared to the IL-15 molecule alone.
    Type: Grant
    Filed: December 25, 2014
    Date of Patent: February 19, 2019
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Xiangdong Qu, Xin Ye, Jijun Yuan, Lei Zhang, Kan Chen, Lianshan Zhang, Guoqing Cao, Zhibin Xu, Weikang Tao
  • Nucleic acids encoding chemokine receptor binding polypeptides
    Patent number: 10174118
    Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: January 8, 2019
    Assignee: Novartis AG
    Inventors: Michelle Bradley, Zarin Brown, Steven John Charlton, Karen Cromie, Bruno Dombrecht, Soren Steffensen, Gino Anselmus Van Heeke
  • Targeting NCchannel for organ protection following ischemic episode
    Patent number: 10166244
    Abstract: The present invention concerns protection of an organ or tissue outside of the central nervous system following an ischemic episode. In particular aspects, the invention concerns organ preservation for transplantation, angina pectoris, kidney reperfusion injury, and so forth. In specific embodiments, the organ is subjected to an inhibitor of an NCCa-ATP channel that is regulated by SUR1. Exemplary inhibitors include sulfonylurea compounds, such as glibenclamide, for example.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: January 1, 2019
    Assignees: University of Maryland, Baltimore, The United States of America as Represented by the Department of Veteran Affairs
    Inventor: J. Marc Simard
  • Method and kit for cytokine analysis from a human whole blood sample
    Patent number: 10161936
    Abstract: The invention relates to a method for prognostic evaluation of the disease progression of rheumatoid arthritis, in particular prognostic evaluation of the disease progression during treatment, and for the diagnosis and/or activity determination of rheumatoid arthritis by analysing cytokines from a human full blood sample. In the method according to the invention, a volume of a full blood sample of a human is transferred into at least one test tube containing a stimulating agent. As control samples, the same volume of a full blood sample of the human in each case is transferred into an empty test tube as a negative control and a test tube containing lipopolysaccharide as a positive control respectively. After incubation, the concentration of at least one proinflammatory cytokine is determined from the cell-free residue of each test tube.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: December 25, 2018
    Assignee: UNIVERSITY OF LEIPZIG
    Inventor: Ulf Wagner
  • Methods for treating or preventing asthma by administering an IL-4R antagonist
    Patent number: 10137193
    Abstract: The invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods featured in the invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: November 27, 2018
    Assignees: Sanofi Biotechnology, Regeneron Pharmaceuticals, Inc.
    Inventors: Gianluca Pirozzi, Franck Skobieranda, Yongtao Li, Neil Graham, Steven P. Weinstein
  • Factor H for the treatment of chronic nephropathies and production thereof
    Patent number: 10137165
    Abstract: The invention relates to the use of Factor H for the manufacture of a medicament to treat both chronic nephropathies which are not causally associated with proteinuria and chronic nephropathies which are causally associated with proteinuria. The invention also relates to large scale purification methods for Factor H.
    Type: Grant
    Filed: November 1, 2010
    Date of Patent: November 27, 2018
    Assignee: CSL BEHRING GMBH
    Inventors: Peter Gronski, Christoph Licht, Bernd Hoppe, Peter Zipfel, Christine Skerka
  • Vaccines with interleukin-33 as an adjuvant
    Patent number: 10130705
    Abstract: Disclosed herein is a vaccine comprising an antigen and IL-33. Also disclosed herein is a method for increasing an immune response in a subject in need thereof. Further disclosed herein is a method for treating cancer in a subject in need thereof. The methods may comprise administering the vaccine to the subject.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: November 20, 2018
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.
    Inventors: David Weiner, Daniel Villarreal, Matthew Morrow, Jian Yan
  • Modulation of yeast-based immunotherapy products and responses
    Patent number: 10117915
    Abstract: Disclosed are methods to modulate yeast-based immunotherapy products and the immune responses, prophylactic responses, and/or therapeutic responses elicited by such products. Also disclosed are modified yeast-based immunotherapy products, kits and compositions.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: November 6, 2018
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Donald Bellgrau, Beth Tamburini
  • Methods of aiding in the diagnosis of diseases using anti-IL-6 antibodies
    Patent number: 10117955
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: November 6, 2018
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Leon Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Olson Anderson, Benjamin H. Dutzar, John A. Latham, Brian R. Kovacevich, Jeffrey T. L. Smith, Mark Litton, Randall C. Schatzman
  • Anti-interleukin-33 antibodies and uses thereof
    Patent number: 10093730
    Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: October 9, 2018
    Assignee: Genentech, Inc.
    Inventors: Philip E. Hass, Meredith Hazen, Yi-Chun Hsiao, Rajita Khosla, Gerald R. Nakamura, Dhaya Seshasayee, Menno Van Lookeren Campagne, Hongkang Xi, Wenwu Zhai, Jack Bevers, III, Nancy Chiang
  • GM-CSF and IL-4 conjugates, compositions, and methods related thereto
    Patent number: 10093709
    Abstract: In certain embodiments, this disclosure relates to conjugates comprising a polypeptide of GM-CSF and a polypeptide IL-4. Typically, the GM-CSF and IL-4 are connected by a linker, e.g., polypeptide. In certain embodiments, the disclosure relates to isolated nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such nucleic acids.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: October 9, 2018
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Jacques Galipeau, Jiusheng Deng
  • Heterodimers of IL-15 and IL-15R alpha to increase thymic output and to treat lymphopenia
    Patent number: 10093710
    Abstract: The present invention provides method for promoting the maturation and export of T cells from thymic tissue by contacting the thymic tissue with supraphysiological levels of interleukin (IL)-15. The present invention also provides methods for preventing, alleviating, reducing, and/or inhibiting lymphopenia or peripheral depletion of lymphocytes in a patient in need thereof by administering to the patient IL-15.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: October 9, 2018
    Assignee: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: George N. Pavlakis, Barbara K. Felber, Antonio Valentin, Cristina Bergamaschi
  • Antagonists of IL-6 to prevent or treat thrombosis
    Patent number: 10093732
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: October 9, 2018
    Assignee: ALDERBIO HOLDINGS LLC
    Inventor: Jeffrey T. L. Smith
  • Use of interleukin-27 as a diagnostic biomarker for bacterial infection in critically ill patients
    Patent number: 10078086
    Abstract: Embodiments of the invention are directed to methods of diagnosing bacterial infection in a critically ill patient. The methods include obtaining a sample from the patient and determining the patient's level of IL-27 expression. Embodiments of the invention are also directed to methods that include determining both the patient's levels of IL-27 expression and PCT expression and using the combined result to provide a diagnosis of bacterial infection in a critically ill patient.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: September 18, 2018
    Assignee: Childrens Hospital Medical Center
    Inventor: Hector R. Wong